Sorted By Test Name - Mayo Medical Laboratories

LVZV
81241
FVEGF
91765
VIP
8150
Negative (reported as positive or negative)
Clinical References: 1. Kennedy PG: Latent varicella-zoster virus is located predominantly in
neurons in human trigeminal ganglia. Proc Natl Acad Sci USA 1998;95:4658-4662 2. McPherson RE:
Herpes zoster ophthalmicus and the immunocompromised host: a case report and review. J Am Optom
Assoc 1997;68:527-538 3. Papanicolaou GA, Meyers BR, Fuchs WS, et al: Infectious ocular
complications in orthotopic liver transplant patients. Clin Infect Dis 1997;24:1172-1177 4. Flamholc L:
Neurological complications in herpes zoster. Scand J Infect Dis 1996;100:35-40
Varicella-Zoster Virus, Molecular Detection, PCR
Clinical Information: Varicella-zoster virus (VZV) causes both varicella (chickenpox) and herpes
zoster (shingles). VZV produces a generalized vesicular rash on the dermis (chickenpox) in normal
children, usually before 10 years of age. After primary infection with VZV, the virus persists in latent
form and may emerge (usually in adults 50 years of age and older) clinically to cause a unilateral
vesicular eruption, generally in a dermatomal distribution (shingles).
Useful For: Rapid (qualitative) detection of varicella-zoster virus DNA in clinical specimens for
laboratory diagnosis of disease due to this virus
Interpretation: Detection of varicella-zoster virus DNA in clinical specimens supports the clinical
diagnosis of infection due to this virus.
Reference Values:
Not applicable
Clinical References: 1. Cinque P, Bossolasco S, Vago L, et al: Varicella-zoster virus (VZV) DNA in
cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central
nervous system or subclinical reactivation of VZV infection? Clin Infect Dis 1997;25(3):634-639 2.
Brown M, Scarborough M, Brink N, et al: Varicella zoster virus-associated neurological disease in
HIV-infected patients. Int J STD AIDS 2001;12(2):79-83 3. Studahl M, Hagberg L, Rekabdar E,
Bergstrom T: Herpesvirus DNA detection in cerebrospinal fluid: differences in clinical presentation
between alpha-, beta-, and gamma-herpesviruses. Scand J Infect Dis 2000;32(3):237-248 4. Iten A,
Chatelard P, Vuadens P, et al: Impact of cerebrospinal fluid PCR on the management of HIV-infected
patients with varicella-zoster virus infection of the central nervous system. J Neurovirol
1999;5(2):172-180
Vascular Endothelial Growth Factor (VEGF), ELISA
Reference Values:
VEGF: 31 – 86 pg/mL
This test was performed using a kit that has not been approved or cleared by the FDA. The analytical
performance characteristics of this test have been determined by Quest Diagnostics Nichols Institute. This
test should not be used for diagnosis without confirmation by other medically established means.
Test Performed by: Quest Diagnostics Nichols Institute
33608 Ortega Highway
San Juan Capistrano, CA 92690-6130
Vasoactive Intestinal Polypeptide (VIP), Plasma
Clinical Information: Vasoactive intestinal polypeptide (VIP) was originally isolated from porcine
small intestine and was recognized by its potent vasodilator activity. This brain/gut hormone has
widespread distribution and is present in neuronal cell bodies localized in the central nervous system,
digestive, respiratory, and urogenital tracts, exocrine glands, and thyroid and adrenal glands. VIP has a
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1840